Posted by Michael Wonder on 01 May 2024
Eton Pharmaceuticals announces submission to FDA of new drug application for ET-400 (hydrocortisone oral solution)
30 April 2024 - Company anticipates 10 month review for potential approval in Q1, 2025.
Eton Pharmaceuticals today announced the submission of a new drug application to the US FDA for approval of ET-400, Eton’s proprietary patented formulation of hydrocortisone oral solution.
